Longitudinal plasma proteomics predict phenoconversion to clinically manifest ALS
Open Access
- 27 July 2026
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3417-3429
Abstract
The study of pre-symptomatic amyotrophic lateral sclerosis (ALS) and the design of disease prevention trials are greatly hampered by our inability to predict which unaffected carriers of ALS-associated pathogenic variants will phenoconvert to clinically manifest disease and when. In this longitudinal Olink Explore, high-throughput, proteomic study, 516 serially collected plasma samples from 33 phenoconverters, 35 patients with ALS, 10 pre-symptomatic pathogenic variant carriers and 59 controls were included. Here we identified 92 proteins with concentrations that changed before phenoconversion; characterized the longitudinal trajectory of these proteins and identified a core panel of 19 proteins which, collectively, predicted phenoconversion over the 0.5-year to 5-year time horizons (crossvalidated areas under the curve 0.80–0.89) and yielded estimates of time to phenoconversion with a mean absolute error of 1.6 years. These findings were partially replicated in UK Biobank data, confirming pre-symptomatic increases in several proteins (for example, NEFL, EDA2R and CA3) and that a multi-protein panel outperformed NEFL alone in estimating time to phenoconversion. This work sheds light on the biology of pre-symptomatic ALS. Moreover, our identification of a panel of new susceptibility/risk biomarkers based on empirical longitudinal data furthers the ultimate goal of ALS prevention.Keywords
Funding Information
- National Institutes of Health (R01 NS105479, U54 NS092091)
- National Institutes of Health (R01 NS105479, U54 NS092091)
- National Institutes of Health (R01 NS105479)
- National Institutes of Health (R01 NS105479)
- National Institutes of Health (R01 NS105479, U54 NS092091)
- Muscular Dystrophy Association (4365, 172123)
- Muscular Dystrophy Association (4365, 172123)
- Muscular Dystrophy Association (4365, 172123)
- ALS Association (2015, 16-TACL-242)
- ALS Association (2015, 16-TACL-242)
- ALS Association (2015, 16-TACL-242)
- ALS Recovery Fund and Kimmelman Estate
This publication has 43 references indexed in Scilit:
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Metabolic alterations precede neurofilament changes in presymptomatic ALS gene carriersEBioMedicine, 2023
- Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS StudyNeurotherapeutics, 2022
- Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide AnalysisMolecular & Cellular Proteomics, 2021
- Megf10 deficiency impairs skeletal muscle stem cell migration and muscle regenerationFEBS Open Bio, 2020
- Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosisJournal of Neurology, 2019
- Sarcolemmal loss of active nNOS (Nos1) is an oxidative stress‐dependent, early event driving disuse atrophyThe Journal of Pathology, 2018
- Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversionAnnals of Neurology, 2018
- The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression modelAlzheimer's & Dementia, 2016
- ALS biomarkers for therapy development: State of the field and future directionsMuscle & Nerve, 2015